
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

Valsamo “Elsa” Anagnostou, MD, PhD, is the Alex Grass professor of oncology at the Johns Hopkins University School of Medicine. Anagnostou also serves as the co-director of the Upper Aerodigestive Malignancies and Cancer Genetics and Epigenetics Programs, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence at the Sidney Kimmel Cancer Center at Johns Hopkins.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.